BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy 2018;38:588-96. [PMID: 29393514 DOI: 10.1002/phar.2089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Cruz-gonzález I, Ince H, Kische S, Schmitz T, Schmidt B, Gori T, Foley D, de Potter T, Tschishow W, Vireca E, Stein K, Boersma LV. Cierre de orejuela izquierda en pacientes mayores de 85 años: seguridad y eficacia del registro EWOLUTION. Revista Española de Cardiología 2020;73:21-7. [DOI: 10.1016/j.recesp.2019.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cruz-González I, Ince H, Kische S, Schmitz T, Schmidt B, Gori T, Foley D, de Potter T, Tschishow W, Vireca E, Stein K, Boersma LV. Left atrial appendage occlusion in patients older than 85 years. Safety and efficacy in the EWOLUTION registry. Rev Esp Cardiol (Engl Ed) 2020;73:21-7. [PMID: 30956034 DOI: 10.1016/j.rec.2019.02.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Zhou L, Ding Y, Gao Y, Yang B, Bao J, Ma J. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1-9. [DOI: 10.1080/17425255.2020.1711883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M, Baquet M, Fischer J, Theiss H, Todaro D, Chieffo A, Presbitero P, Colombo A, Massberg S, Tamburino C, Mehilli J. Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2019;12:1566-76. [PMID: 31202946 DOI: 10.1016/j.jcin.2019.03.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
5 Tana C, Lauretani F, Ticinesi A, Prati B, Nouvenne A, Meschi T. Molecular and Clinical Issues about the Risk of Venous Thromboembolism in Older Patients: A Focus on Parkinson's Disease and Parkinsonism. Int J Mol Sci 2018;19:E1299. [PMID: 29701703 DOI: 10.3390/ijms19051299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
6 Kawashima H, Watanabe Y, Hioki H, Kozuma K, Kataoka A, Nakashima M, Nagura F, Nara Y, Yashima F, Tada N, Naganuma T, Yamawaki M, Yamanaka F, Shirai S, Mizutani K, Tabata M, Ueno H, Takagi K, Yamamoto M, Hayashida K. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR. JACC: Cardiovascular Interventions 2020;13:2587-97. [DOI: 10.1016/j.jcin.2020.09.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
7 Haas S, Camm AJ, Bassand J, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal 2019;213:35-46. [DOI: 10.1016/j.ahj.2019.03.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
8 Savinova AV, Dobrodeeva VS, Petrova MM, Nasyrova RF, Shnayder NA. Pharmacokinetics and Pharmacogenetics of Dabigatran. Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:146-52. [DOI: 10.20996/1819-6446-2021-01-04] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Furlan G, Caduff-Janosa P, Sottosanti L, Cappello E, Valdiserra G, Tuccori M. Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward. Drug Saf 2020;43:853-66. [PMID: 32500271 DOI: 10.1007/s40264-020-00949-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Shnayder NA, Petrova MM, Shesternya PA, Savinova AV, Bochanova EN, Zimnitskaya OV, Pozhilenkova EA, Nasyrova RF. Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines 2021;9:451. [PMID: 33922084 DOI: 10.3390/biomedicines9050451] [Reference Citation Analysis]
11 Falamić S, Lucijanić M, Ortner-Hadžiabdić M, Marušić S, Bačić-Vrca V. Pharmacists' interventions improve health-related quality of life of rural older person on warfarin: a randomized controlled trial. Sci Rep 2021;11:21897. [PMID: 34754004 DOI: 10.1038/s41598-021-01394-0] [Reference Citation Analysis]
12 Devane CL. Anticoagulation Research and Awareness-A Cross-Therapeutic Need. Pharmacotherapy 2018;38:586-7. [DOI: 10.1002/phar.2123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lewis J, Gregorian T, Portillo I, Goad J. Drug interactions with antimalarial medications in older travelers: a clinical guide. Journal of Travel Medicine 2020;27:taz089. [DOI: 10.1093/jtm/taz089] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang X, Chen GY, Wang ZX, Li XH, Luo R, Li YG, Yang F, Zhou X, Jiang F, Wang YS. Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation. Ann Transl Med 2020;8:1008. [PMID: 32953808 DOI: 10.21037/atm-20-5387] [Reference Citation Analysis]
15 Tsai CT, Liao JN, Chen SJ, Jiang YR, Chen TJ, Chao TF. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years. Eur J Clin Invest 2021;51:e13488. [PMID: 33420738 DOI: 10.1111/eci.13488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Shendre A, Dillon C, Limdi NA. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics 2018;19:1357-71. [PMID: 30345882 DOI: 10.2217/pgs-2018-0146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
17 Nugent BM, Madabushi R, Buch B, Peiris V, Crentsil V, Miller VM, Bull J, R Jenkins M. Heterogeneity in treatment effects across diverse populations. Pharm Stat 2021. [PMID: 34396690 DOI: 10.1002/pst.2161] [Reference Citation Analysis]
18 Henderson LM, Robinson RF, Ray L, Khan BA, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clin Transl Sci 2019;12:312-20. [PMID: 30821933 DOI: 10.1111/cts.12611] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Avarello I, Bianchi S, Toschi V, Zighetti ML, Faioni EM. Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity. Thromb Res 2021;203:18-21. [PMID: 33901765 DOI: 10.1016/j.thromres.2021.04.011] [Reference Citation Analysis]